Pacific Biosciences
PACB
#3500
Rank
$2.50 B
Marketcap
$11.09
Share price
0.18%
Change (1 day)
-0.81%
Change (1 year)

P/E ratio for Pacific Biosciences (PACB)

P/E ratio as of January 2023 (TTM): -8.23

According to Pacific Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.23425. At the end of 2021 the company had a P/E ratio of -23.0.

P/E ratio history for Pacific Biosciences from 2011 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2021-23.0-110.63%
2020216-2415.57%
2019-9.34-2.86%
2018-9.61223.99%
2017-2.97
2015-30.5266.11%
2014-8.34102.53%
2013-4.12311.81%
2012-1.0000

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
31.2-478.37%๐Ÿ‡บ๐Ÿ‡ธ USA
-14.5 76.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-8.08-1.93%๐Ÿ‡บ๐Ÿ‡ธ USA
27.8-438.08%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
-3.44-58.27%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.